Rapid antidepressant actions of scopolamine: Role of medial prefrontal cortex and M1-subtype muscarinic acetylcholine receptors

Neurobiology of Disease

Volumn 82, Issue , 2015, Pages 254-261

  Navarria, Andrea ^a,b   Wohleb, Eric S ^a   Voleti, Bhavya ^a   Ota, Kristie T ^a   Dutheil, Sophie ^a   Lepack, Ashley E ^a   Dwyer, Jason M ^a   Fuchikami, Manabu ^a   Becker, Astrid ^a   Drago, Filippo ^b   Duman, Ronald S ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CATANIA   (Italy)

Author keywords

Anhedonia; Depression; Glutamate; Neuronal silencing; Stress

Indexed keywords

ANTIDEPRESSANT AGENT; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MULTIPROTEIN COMPLEX; MUSCARINIC M1 RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; N-(3-OXO-3-(4-(PYRIDIN-4-YL)PIPERAZIN-1-YL)PROPYL)BENZO(C)(1,2,5)THIADIAZOLE-4-SULFONAMIDE; PROTEIN C FOS; SCOPOLAMINE BROMIDE; SUGAR INTAKE; SULFONAMIDE; TARGET OF RAPAMYCIN KINASE; THIADIAZOLE DERIVATIVE;

ANHEDONIA; ANIMAL; ANTAGONISTS AND INHIBITORS; CHRONIC DISEASE; DISEASE MODEL; DRUG EFFECTS; DRUG THERAPY; MALE; MENTAL STRESS; METABOLISM; MICROINJECTION; PHYSIOLOGY; PREFRONTAL CORTEX; SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT; SUGAR INTAKE; TIME FACTOR; TISSUE CULTURE TECHNIQUE;

ANHEDONIA; ANIMALS; ANTIDEPRESSIVE AGENTS; CHRONIC DISEASE; DIETARY SUCROSE; DISEASE MODELS, ANIMAL; MALE; MICROINJECTIONS; MULTIPROTEIN COMPLEXES; MUSCARINIC ANTAGONISTS; PREFRONTAL CORTEX; PROTO-ONCOGENE PROTEINS C-FOS; RATS, SPRAGUE-DAWLEY; RECEPTOR, MUSCARINIC M1; SCOPOLAMINE HYDROBROMIDE; SIGNAL TRANSDUCTION; STRESS, PSYCHOLOGICAL; SULFONAMIDES; THIADIAZOLES; TIME FACTORS; TISSUE CULTURE TECHNIQUES; TOR SERINE-THREONINE KINASES;

EID: 84934269718     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2015.06.012     Document Type: Article

References (36)

1. Berman R.M., Cappiello A., Anand A., Oren D.A., Heninger G.R., Charney D.S., et al. Antidepressant effects of ketamine in depressed patients. Biol. Psychiatry 2000, 47(4):351-354.
2. Ceccatelli S., Villar M.J., Goldstein M., Hokfelt T. Expression of c-Fos immunoreactivity in transmitter-characterized neurons after stress. Proc. Natl. Acad. Sci. U. S. A. 1989, 86(23):9569-9573.
3. Cota D., Proulx K., Smith K.A., Kozma S.C., Thomas G., Woods S.C., et al. Hypothalamic mTOR signaling regulates food intake. Science 2006, 312(5775):927-930.
4. Drevets W.C., Furey M.L. Replication of scopolamine's antidepressant efficacy in major depressive disorder: a randomized, placebo-controlled clinical trial. Biol. Psychiatry 2010, 67(5):432-438.
5. Drevets W.C., Price J.L., Furey M.L. Brain structural and functional abnormalities in mood disorders: implications for neurocircuitry models of depression. Brain Struct. Funct. 2008, 213(1-2):93-118.
6. Duman R.S., Aghajanian G.K. Synaptic dysfunction in depression: potential therapeutic targets. Science 2012, 338(6103):68-72.
7. Elsayed M., Banasr M., Duric V., Fournier N.M., Licznerski P., Duman R.S. Antidepressant effects of fibroblast growth factor-2 in behavioral and cellular models of depression. Biol. Psychiatry 2012, 72(4):258-265.
8. Fournier J.C., DeRubeis R.J., Hollon S.D., Dimidjian S., Amsterdam J.D., Shelton R.C., et al. Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA 2010, 303(1):47-53.
9. Fuchikami M., Thomas A.M., Liu R.J., Wohleb E.S., Land B.B., DiLeone R.J., Aghajanian G.K., Duman R.S. Optogenetic stimulation of infralimbic PFC reproduces ketamine's rapid and sustained actions. Proc. Natl. Acad. Sci. U. S. A. 2015, (epub ahead of press).
10. Furey M.L., Drevets W.C. Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial. Arch. Gen. Psychiatry 2006, 63(10):1121-1129.
11. Golding J.F., Stott J.R. Comparison of the effects of a selective muscarinic receptor antagonist and hyoscine (scopolamine) on motion sickness, skin conductance and heart rate. Br. J. Clin. Pharmacol. 1997, 43(6):633-637.
12. Hoffman G.E., Lyo D. Anatomical markers of activity in neuroendocrine systems: are we all 'fos-ed out'?. J. Neuroendocrinol. 2002, 14(4):259-268.
13. Kessler R.C., Berglund P., Demler O., Jin R., Koretz D., Merikangas K.R., et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003, 289(23):3095-3105.
14. Laurent V., Westbrook R.F. Inactivation of the infralimbic but not the prelimbic cortex impairs consolidation and retrieval of fear extinction. Learn. Mem. 2009, 16(9):520-529.
15. Li N., Lee B., Liu R.J., Banasr M., Dwyer J.M., Iwata M., et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 2010, 329(5994):959-964.
16. Li N., Liu R.J., Dwyer J.M., Banasr M., Lee B., Son H., et al. Glutamate N-methyl-d-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure. Biol. Psychiatry 2011, 69(8):754-761.
17. Liu R.J., Aghajanian G.K. Stress blunts serotonin- and hypocretin-evoked EPSCs in prefrontal cortex: role of corticosterone-mediated apical dendritic atrophy. Proc. Natl. Acad. Sci. U. S. A. 2008, 105(1):359-364.
18. MacQueen G.M., Yucel K., Taylor V.H., Macdonald K., Joffe R. Posterior hippocampal volumes are associated with remission rates in patients with major depressive disorder. Biol. Psychiatry 2008, 64(10):880-883.
19. Medalla M., Barbas H. The anterior cingulate cortex may enhance inhibition of lateral prefrontal cortex via m2 cholinergic receptors at dual synaptic sites. J. Neurosci. 2012, 32(44):15611-15625.
20. Moghaddam B., Adams B., Verma A., Daly D. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J. Neurosci. 1997, 17(8):2921-2927.
21. Moriya H., Takagi Y., Nakanishi T., Hayashi M., Tani T., Hirotsu I. Affinity profiles of various muscarinic antagonists for cloned human muscarinic acetylcholine receptor (mAChR) subtypes and mAChRs in rat heart and submandibular gland. Life Sci. 1999, 64(25):2351-2358.
22. Papakostas G.I. Limitations of contemporary antidepressants: tolerability. J. Clin. Psychiatry 2007, 68(Suppl. 10):11-17.
23. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates 2007, Academic Press/Elsevier, Amsterdam; Boston. 6th edn.
24. Peng Z.C., Chen S., Bentivoglio M. A sensitive double immunostaining protocol for Fos-immunoreactive neurons. Brain Res. Bull. 1995, 36(1):101-105.
25. Radley J.J., Sisti H.M., Hao J., Rocher A.B., McCall T., Hof P.R., et al. Chronic behavioral stress induces apical dendritic reorganization in pyramidal neurons of the medial prefrontal cortex. Neuroscience 2004, 125(1):1-6.
26. Radley J.J., Rocher A.B., Miller M., Janssen W.G., Liston C., Hof P.R., et al. Repeated stress induces dendritic spine loss in the rat medial prefrontal cortex. Cereb. Cortex 2006, 16(3):313-320.
27. Roldan G., Bolanos-Badillo E., Gonzalez-Sanchez H., Quirarte G.L., Prado-Alcala R.A. Selective M1 muscarinic receptor antagonists disrupt memory consolidation of inhibitory avoidance in rats. Neurosci. Lett. 1997, 230(2):93-96.
28. Sagar S.M., Sharp F.R., Curran T. Expression of c-fos protein in brain: metabolic mapping at the cellular level. Science 1988, 240(4857):1328-1331.
29. Sheffler D.J., Williams R., Bridges T.M., Xiang Z., Kane A.S., Byun N.E., et al. A novel selective muscarinic acetylcholine receptor subtype 1 antagonist reduces seizures without impairing hippocampus-dependent learning. Mol. Pharmacol. 2009, 76(2):356-368.
30. Sierra-Mercado D., Padilla-Coreano N., Quirk G.J. Dissociable roles of prelimbic and infralimbic cortices, ventral hippocampus, and basolateral amygdala in the expression and extinction of conditioned fear. Neuropsychopharmacology 2011, 36(2):529-538.
31. Voleti B., Navarria A., Liu R.J., Banasr M., Li N., Terwilliger R., et al. Scopolamine rapidly increases mammalian target of rapamycin complex 1 signaling, synaptogenesis, and antidepressant behavioral responses. Biol. Psychiatry 2013, 74(10):742-749.
32. Willner P. Validity, reliability and utility of the chronic mild stress model of depression: a 10-year review and evaluation. Psychopharmacology 1997, 134(4):319-329.
33. Willner P., Towell A., Sampson D., Sophokleous S., Muscat R. Reduction of sucrose preference by chronic unpredictable mild stress, and its restoration by a tricyclic antidepressant. Psychopharmacology 1987, 93(3):358-364.
34. Witkin J.M., Overshiner C., Li X., Catlow J.T., Wishart G.N., Schober D.A., et al. M1 and m2 muscarinic receptor subtypes regulate antidepressant-like effects of the rapidly acting antidepressant scopolamine. J. Pharmacol. Exp. Ther. 2014, 351(2):448-456.
35. Xiang Z., Thompson A.D., Jones C.K., Lindsley C.W., Conn P.J. Roles of the M1 muscarinic acetylcholine receptor subtype in the regulation of basal ganglia function and implications for the treatment of Parkinson's disease. J. Pharmacol. Exp. Ther. 2012, 340(3):595-603.
36. Zarate C.A., Singh J.B., Carlson P.J., Brutsche N.E., Ameli R., Luckenbaugh D.A., et al. A randomized trial of an N-methyl-d-aspartate antagonist in treatment-resistant major depression. Arch. Gen. Psychiatry 2006, 63(8):856-864.